Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancer

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 465-471

  Knight, Lucy J ^a,c   Burrage, Joseph ^a   Bujac, Sarah R ^a   Haggerty, Carolyn ^a   Graham, Alexander ^a   Gibson, Neil J ^a   Ellison, Gillian ^a   Growcott, James W ^a   Brooks, A Nigel ^a   Hughes, Andrew M ^a   Xinarianos, George ^b   Nikolaidis, Georgios ^b   Field, John K ^b   Liloglou, Triantafillos ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c IQVIA   (United States)

Author keywords

Endothelial A receptor; Endothelin 1; Endothelin B receptor; Gene methylation; Non small cell lung cancer

Indexed keywords

ENDOTHELIN B RECEPTOR;

ADULT; AGED; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; FEMALE; GENE SILENCING; GENETIC REGULATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; SQUAMOUS CELL CARCINOMA;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DINUCLEOTIDE REPEATS; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RECEPTOR, ENDOTHELIN B; RNA, MESSENGER; RNA, NEOPLASM;

EID: 64549162452     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000171     Document Type: Article

References (41)

1. Bagnato A and Natali PG: Endothelin receptors as novel targets in tumor therapy. J Transl Med 2: 16, 2004.
2. Arun C, DeCatris M, Hemingway DM, London NJ and O'Byrne KJ: Endothelin-1 is a novel prognostic factor in nonsmall cell lung cancer. Int J Biol Markers 19: 262-267, 2004.
3. Jerónimo C, Henrique R, Campos PF, Oliveira J, Caballero OL, Lopes C and Sidransky D: Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 56: 52-55, 2003.
4. Nelson J, Bagnato A, Battistini B and Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116, 2003.
5. Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ and Webb DJ: Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92: 2148-2152, 2005.
6. Chen SC, Lin CY, Chen YH, Fang HY, Cheng CY, Chang CW, Chen RA, Tai HL, Lee CH, Chou MC, Lin TS and Hsu LS: Aberrant promoter methylation of EDNRB in lung cancer in Taiwan. Oncol Rep 15: 167-172, 2006.
7. Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1: R50-R59, 2007.
8. Jones PA: The DNA methylation paradox. Trends Genet 15: 34-37, 1999.
9. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006.
10. Brena RM and Costello JF: Genome-epigenome interactions in cancer. Hum Mol Genet 16 Spec No 1: R96-R105, 2007.
11. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993, 2004.
12. Shaw RJ, Hall GL, Lowe D, Bowers NL, Liloglou T, Field JK, Woolgar JA and Risk JM: CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncol 43: 878-886, 2007.
13. O'Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amorosino M and Farraye FA: Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end-points. Am J Surg Pathol 30: 1491-1501, 2006.
14. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, Nelson HH, Karagas MR and Kelsey KT: Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 66: 10621-10629, 2006.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
16. Ehrich M, Field JK, Liloglou T, Xinarianos G, Oeth P, Nelson MR, Cantor CR and van den Boom D: Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 66: 10911-10918, 2006.
17. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK and van den Boom D: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 102: 15785-15790, 2005.
18. Xinarianos G, McRonald FE, Risk JM, Bowers NL, Nikolaidis G, Field JK and Liloglou T: Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in nonsmall cell lung cancer. Hum Mol Genet 15: 2038-2044, 2006.
19. Field JK, Liloglou T, Warrak S, Burger M, Becker E, Berlin K, Nimmrich I and Maier S: Methylation discriminators in NSCLC identified by a microarray based approach. Int J Oncol 27: 105-111, 2005.
20. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam C-L, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF and Minna JD: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: E486, 2006.
21. Toyooka S, Tokumo M, Shigematsu H, Matsuo K, Asano H, Tomii K, Ichihara S, Suzuki M, Aoe M, Date H, Gazdar AF and Shimizu N: Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66: 1371-1375, 2006.
22. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB and Gazdar AF: Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247: 56-71, 2007.
23. Belinsky SA, Grimes MJ, Casas E, Stidley CA, Franklin WA, Bocklage TJ, Johnson DH and Schiller JH: Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 96: 1278-1283, 2007.
24. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA and Picchi MA: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11: 6505-6511, 2005.
25. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA and Byers T: Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66: 3338-3344, 2006.
26. Cirincione R, Lintas C, Conte D, Mariani L, Roz L, Vignola AM, Pastorino U and Sozzi G: Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 118: 1248-1253, 2006.
27. 16INK4A Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 8: 3782-3787, 2002.
28. Wang YC, Hsu HS, Chen TP and Chen JT: Molecular diagnostic markers for lung cancer in sputum and plasma. Ann NY Acad Sci 1075: 179-184, 2006.
29. Lo KW, Tsang YS, Kwong J, To KF, Teo PM and Huang DP: Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 98: 651-655, 2002.
30. Eberle J, Weitmann S, Thieck O, Pech H, Paul M and Orfanos CE: Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 112: 925-932, 1999.
31. Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG and Bova GS: Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57: 35-37, 1997.
32. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC and von Ruecker A: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11: 4097-4106, 2005.
33. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB and Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64: 1975-1986, 2004.
34. Singal R, Ferdinand L, Reis IM and Schlesselman JJ: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 12: 631-637, 2004.
35. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Muller SC and von Rucker A: Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 51: 665-674, 2007.
36. Rogers CG, Gonzalgo ML, Yan G, Bastian PJ, Chan DY, Nelson WG and Pavlovich CP: High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J Urol 176: 2280-2284, 2006.
37. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC and Catto JW: Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 13: 2046-2053, 2007.
38. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD and Nelson JB: Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 246: 139-148, 2007.
39. Zhao YD, Springall DR, Hamid Q, Levene M and Polak JM: Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors. J Cardiovasc Pharmacol 26 (Suppl. 3): S341-S345, 1995.
40. Giaid A, Hamid QA, Springall DR, Yanagisawa M, Shinmi O, Sawamura T, Masaki T, Kimura S, Corrin B and Polak JM: Detection of endothelin immunoreactivity and mRNA in pulmonary tumours. J Pathol 162: 15-22, 1990.
41. Yang X, Liu L and Qi H: Study on endothelin-1 positive expression and quantitative analysis in lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 21: 111-113, 1998.